AtriCure (NASDAQ:ATRC Shareholders Incur Further Losses as Stock Declines 9.8% This Week, Taking Three-year Losses to 73%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of AtriCure, Inc. (NASDAQ:AT
AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target
AtriCure(ATRC.US) Officer Sells US$36,135 in Common Stock
$AtriCure(ATRC.US)$ Officer Noznesky Justin J sold 1,500 shares of common stock on May 1, 2024 at an average price of $24.09 for a total value of $36,135.Source: Announcement What is statement of chan
The Past Three Years for AtriCure (NASDAQ:ATRC) Investors Has Not Been Profitable
AtriCure Price Target Cut to $49.00/Share From $57.00 by Canaccord Genuity
AtriCure Price Target Cut to $49.00/Share From $57.00 by Canaccord Genuity
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
AtriCure Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results. Also, Needham and JP Morgan Lowered Their Respective Price Targets on the Stock.
AtriCure Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results. Also, Needham and JP Morgan Lowered Their Respective Price Targets on the Stock.
AtriCure Is Maintained at Overweight by JP Morgan
AtriCure Is Maintained at Overweight by JP Morgan
Komo: Maintaining the AtriCure (ATRC.US) rating, adjusted from an increase in holdings to an increase in holdings rating, and the target price was adjusted from $42.00 to $34.00.
Komo: Maintaining the AtriCure (ATRC.US) rating, adjusted from an increase in holdings to an increase in holdings rating, and the target price was adjusted from $42.00 to $34.00.
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $34
JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $42 to $34.
Earnings Call Summary | AtriCure(ATRC.US) Q1 2024 Earnings Conference
The following is a summary of the AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript:Financial Performance:AtriCure's Q1 2024 overall revenue was $109 million, up 16% from Q1 2023.Gross margin rea
Earnings Call: AtriCure Reports Robust Q1 2024 Growth, Reaffirms Guidance
AtriCure Is Maintained at Buy by Needham
AtriCure Is Maintained at Buy by Needham
Needham Maintains Buy on AtriCure, Lowers Price Target to $40
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $46 to $40.
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
AtriCure's Strong Growth and Market Position Justify Buy Rating
Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics
AtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider Losses
ArtiCure Sees FY24 Adj. EPS $(0.82)-$(0.74) Vs $(0.74) Est.; Revenue ~$459M-$466M Vs $461.304M Est.
ArtiCure Sees FY24 Adj. EPS $(0.82)-$(0.74) Vs $(0.74) Est.; Revenue ~$459M-$466M Vs $461.304M Est.
AtriCure Q1 2024 Adj EPS $(0.25) Misses $(0.23) Estimate, Sales $108.851M Beat $106.902M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 8.7 percent decrease over losses of $(0.23) per s
No Data